▶ ADAMAX · SUBTOPIC · DOSING LITERATURE

ADAMAX Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of ADAMAX. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for ADAMAX reports the following route(s) of administration: Subcutaneous (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of ADAMAX.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for ADAMAX of approximately Short plasma (minutes). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of ADAMAX. Refer to the original publication for full protocol detail.

Brines M, Patel NS, Villa P, et al. (2014) reports the ADAMAX protocol used in ARA-290, a non-erythropoietic EPO analog, modulates inflammation and tissue protection, published in Mol Med. See the source for the protocol-level dose range, frequency, and duration. link
Heij L, Niesters M, Swartjes M, et al. (2012) reports the ADAMAX protocol used in Cibinetide (ARA-290) attenuates small-fiber neuropathy in sarcoidosis: a placebo-controlled trial, published in Mol Med. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ Side effects of Adamax?

Limited human safety data. The engineering goal is to avoid the erythropoietic side effects of native EPO; Adamax-class peptides should not raise hematocrit at standard research doses.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · 4 °C, 12+ months

Reconstituted · 2–8 °C, 28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Research chemical.

WADA · EPO-class status under S2 may apply depending on specific analog. Buyers should verify with current WADA list.

◀ ADAMAX OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-20